Business · 29/09/2006Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Pfizer's TARCEVA Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Pfizer's TARCEVA patent extension, as required by law, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →